Disclaimer: Metenolone (Primobolan) is a Class C controlled substance in the UK under the Misuse of Drugs Act 1971. Supply without a licence is a criminal offence. The injectable form (metenolone enanthate) is no longer commercially available in most countries. The oral form (metenolone acetate) retains limited pharmaceutical licensing in some jurisdictions. This guide is educational.
Drug Profile
| Parameter | Detail | |-----------|--------| | Drug class | Androgen / anabolic steroid | | Chemical name | 17β-Hydroxy-1-methyl-5α-androst-1-en-3-one | | Anabolic:Androgenic ratio | 88:44–57 (injectable enanthate) | | Aromatisation | None — cannot aromatise to oestrogen | | 5-alpha reduction | Already a 5α-reduced compound — not further reduced to a more potent DHT | | Hepatotoxicity | Low (oral form is 17-beta esterified, not 17-alpha alkylated — different metabolic pathway) | | Forms | Metenolone enanthate (injectable, IM); Metenolone acetate (oral) | | Half-life | Enanthate: ~10 days; Acetate (oral): ~4–6 hours | | UK legal status | Class C controlled substance | | Notable brand names | Primobolan (Schering, Germany — largely discontinued); Primobolan Depot (injectable, Bayer) |
Background: The Arnold Connection and What It Actually Means
Primobolan's cultural prominence is significantly amplified by its association with Arnold Schwarzenegger, who reportedly acknowledged its use during his bodybuilding era. This has created a mythology around the compound that inflates its reputation in some respects and distorts the risk/benefit picture in others.
What it means practically: primobolan became the compound associated with the "classic physique" era — lean, aesthetic, less water-saturated than testosterone or deca-heavy protocols. This association is not entirely misleading. Primobolan's inability to aromatise does produce a dryer appearance than aromatising compounds. But the mythology has also inflated its perceived potency and "premium" status far beyond what the clinical data supports.
Primobolan injectable (metenolone enanthate) was manufactured by Schering AG (Germany) and was, for decades, the gold standard pharmaceutical form. Schering ceased production. The pharmaceutical injectable product is largely unavailable through legitimate channels globally. The vast majority of "Primobolan" on the grey market is either counterfeit, misrepresented, or produced in unlicensed underground labs. This has practical significance for anyone considering use.
Pharmacological Mechanism
Structure and Key Properties
Metenolone is a DHT derivative with a 1-methyl group and a 1,2-double bond. The combination of these structural features:
-
Eliminates aromatisation: No conversion to oestrogen. This means no oestrogen-related side effects (water retention, gynecomastia via oestrogenic pathway) and also no oestrogen's benefits (joint protection, some cardiovascular effects, mood stabilisation from oestradiol).
-
Reduces androgenic side effects relative to testosterone: The DHT derivative structure with the 1-methyl group and 1,2-double bond produces a compound with moderate anabolic activity and lower androgenic potency than testosterone, despite being DHT-derived.
-
Low SHBG binding: Metenolone binds SHBG with lower affinity than testosterone, meaning more of it circulates as free compound.
-
Oral form not hepatotoxic in the typical AAS sense: Unlike oral 17-alpha alkylated AAS (oxandrolone, stanozolol, oxymesterone), the oral metenolone acetate form is 17-beta esterified — a different modification that does not require the same liver processing as 17-aa compounds. Hepatotoxicity is meaningfully lower than other oral AAS. This is a genuine clinical distinction.
Androgen Receptor Binding
Metenolone's AR binding affinity is moderate — higher than testosterone in some assays, which partly explains the anabolic activity from a relatively low androgenic profile. The 1-methyl group and double bond alter the receptor binding kinetics in ways that favour anabolic over androgenic activity.
The Evidence Base
Pharmaceutical History
Metenolone was originally developed by Squibb and later by Schering. It has had legitimate medical applications:
- Osteoporosis treatment
- Muscle wasting in catabolic disease states
- Aplastic anaemia (limited)
The clinical literature on metenolone is substantially thinner than on testosterone, nandrolone, or oxandrolone. Most of the available clinical evidence is dated (1960s–1980s) and uses the oral acetate form more than the injectable enanthate.
A key early study (Mayer & Mayer, 1977) established metenolone acetate's anabolic effects in men with osteoporosis and wasting. More recent data specifically on metenolone enanthate in humans is limited.
What the Evidence Does and Doesn't Support
Supported: Modest anabolic activity (lean mass preservation, some increase in nitrogen retention), low hepatotoxicity profile (oral form), no oestrogen-related effects, low androgenic side effect profile relative to anabolic activity.
Not well-supported by clinical data: The magnitude of body composition effects at typical non-medical doses is less well-characterised than for testosterone, nandrolone, or oxandrolone. Much of the high-dose efficacy data in humans is anecdotal.
Oral vs. Injectable: A Critical Distinction
The two forms of primobolan are pharmacologically distinct beyond just the delivery route.
Metenolone Enanthate (Injectable)
- Half-life approximately 10 days — once-weekly injection is sufficient for stable levels
- Higher bioavailability — avoids first-pass hepatic metabolism entirely
- Historically the preferred clinical form
- Largely unavailable as genuine pharmaceutical product
Metenolone Acetate (Oral)
- Short half-life (~4–6 hours) requires multiple daily doses to maintain stable blood levels
- Undergoes first-pass metabolism — bioavailability is meaningfully lower than injectable
- Not 17-alpha alkylated — lower hepatotoxicity than other oral AAS
- The orally available form is where the hepatotoxicity advantage over other oral AAS compounds is most relevant
The dose reality: Because of lower bioavailability and lower potency per milligram relative to other AAS, effective non-medical oral metenolone acetate doses that produce meaningful results tend to be high — historical cycle logs typically describe 100–200mg/day. At these doses, even without 17-aa hepatotoxicity, daily oral use carries some liver burden.
Side Effects
Androgenic
Metenolone's androgenic profile is genuinely lower than most other AAS compounds. However:
Hair loss: Despite lower androgenicity overall, metenolone has a reputation for accelerating male pattern hair loss. This is counterintuitive given the lower androgenic rating, but DHT-derived compounds can have disproportionate effects on the scalp relative to their overall androgenic activity. Men with genetic susceptibility should consider this specifically.
Acne: Significantly less than testosterone; relevant in dose-dependent fashion.
Prostate: Less androgenic stimulation than testosterone; PSA monitoring still appropriate.
Cardiovascular
Metenolone does not aromatise, which removes oestrogen-related cardiovascular concerns, but oestrogen's cardioprotective role means the absence of oestrogenic activity carries its own risk dimension.
Lipid impact: Metenolone causes HDL suppression and LDL elevation. The magnitude is generally less severe than stanozolol or trenbolone, but it is real. Studies show HDL reduction of approximately 15–25% at typical doses — less dramatic than some AAS but not negligible over time. [Source: Hartgens F & Kuipers H, 2004 — Effects of androgenic-anabolic steroids in athletes — Sports Medicine, 34(8):513–554]
HPG axis suppression: Complete, as with all exogenous androgens. LH and FSH are suppressed. Testicular atrophy occurs with prolonged use.
Hepatic
The oral form's lower hepatotoxicity compared to 17-aa oral AAS is a genuine and meaningful clinical distinction. The injectable form produces essentially no hepatic stress. Liver enzyme monitoring is still reasonable practice but the specific concern about cholestatic hepatitis and peliosis hepatis associated with 17-aa compounds does not apply to metenolone.
The "Mild" Label: What It Means and Doesn't Mean
Primobolan is frequently described as one of the "mildest" AAS compounds. This label is partly accurate:
- Genuinely lower androgenic side effects than testosterone or trenbolone
- Lower hepatotoxicity (oral form) than standard oral AAS
- No oestrogenic side effects
- Less dramatic HPG axis suppression than stronger androgens (though suppression is still real)
What "mild" does not mean:
- Safe — HPG axis suppression still occurs; cardiovascular impact still occurs; androgenic effects still occur
- Appropriate for beginners — the same reasons a compound with a full medical safety history is a better starting point still apply
- More effective in proportion to its "mildness" — the lower side effect profile comes with a lower anabolic stimulus per milligram compared to testosterone or nandrolone
The Grey Market Problem with Primobolan Specifically
Primobolan's "premium" status in the non-medical market — partly driven by the Arnold mythology, partly by genuine pharmaceutical scarcity — means it commands high prices in the grey market. It is also one of the most frequently counterfeited AAS compounds. Independent testing of products sold as Primobolan regularly finds testosterone (cheaper to produce) or other compounds substituted. This is a direct safety risk: a man who thinks he is running a non-aromatising compound and discovers unexpected oestrogen elevation has been sold something other than metenolone.
Who Might Use This Compound and Why
The clinical contexts where metenolone has been used, and the non-medical rationale:
Wasting conditions, catabolic illness: The low side effect profile makes it one of the more reasonable AAS compounds for clinical use in contexts where muscle preservation is the goal without aggressive anabolic stimulation. This is where it has had genuine medical application.
Female use (historically): Metenolone acetate was one of the more commonly used AAS compounds in women specifically because of the low androgenic rating reducing virilisation risk. This is a legitimate clinical distinction.
Non-medical "lean gains" / "cutting" use: The combination of no water retention (no aromatisation), moderate anabolic activity, and lower androgenic side effects makes primobolan one of the more rationally justified choices for non-medical use among people who are going to use AAS regardless. This is not a recommendation — it is an honest clinical observation.
Monitoring Markers
Baseline: Total testosterone, LH, FSH, lipid panel, liver function, haematocrit, blood pressure
During use:
- Lipid panel (HDL monitoring — 4–6 weeks)
- Liver function (particularly relevant for oral form, though less acute concern than 17-aa compounds)
- Blood pressure
- Haematocrit
Post-use: HPG axis recovery markers — LH, FSH, total testosterone at 6–8 weeks post-cessation
The Short Version
Primobolan is a genuinely distinctive compound within the AAS class — lower androgenic activity relative to anabolic effect, no aromatisation, lower hepatotoxicity (oral form), and a clinical history that makes it more defensible than most compounds in certain contexts. The mythology around it is partly founded in fact. The inflation of its reputation is mostly the Arnold effect.
The practical problems: pharmaceutical injectable primobolan is largely unavailable; grey-market product is heavily counterfeited; the oral form at effective doses requires multiple daily doses; and "mild" does not mean safe — HPG axis suppression, lipid impact, and androgenic effects are real.
If you're evaluating AAS options — primobolan is among the more rational choices on a pure pharmacological risk profile. That's not the same as saying it's a good choice, and it certainly doesn't apply to anyone under 25.
Key references: Hartgens F & Kuipers H, Sports Medicine, 2004; Mayer M & Rosen F, 1975 — interaction of anabolic steroids with glucocorticoid receptor sites; Evans NA, 2004 — Current concepts in anabolic-androgenic steroids — American Journal of Sports Medicine.